Menu Search
Equities

Eisai Co Ltd

4523:TYO

Eisai Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)4,687.00
  • Today's Change68.00 / 1.47%
  • Shares traded756.00k
  • 1 Year change-39.13%
  • Beta0.3140
Data delayed at least 20 minutes, as of Nov 22 2024 04:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform6
Hold6
Sell2
Strong Sell0

Share price forecast in JPY

The 14 analysts offering 12 month price targets for Eisai Co Ltd have a median target of 7,064.00, with a high estimate of 9,700.00 and a low estimate of 4,600.00. The median estimate represents a 52.93% increase from the last price of 4,619.00.
High110.0%9,700.00
Med52.9%7,064.00
Low-0.4%4,600.00

Dividends in JPY

In 2024, Eisai Co Ltd reported a dividend of 160.00 JPY, equaling last years dividend. The 14 analysts covering the company expect dividends of 164.29 JPY for the upcoming fiscal year, an increase of 2.68%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in JPY

On Nov 07, 2024, Eisai Co Ltd reported 2nd quarter 2025 earnings of 39.18 per share. This result exceeded the 28.42 consensus of the 3 analysts covering the company and exceeded last year's 2nd quarter results by 29.46.
The next earnings announcement is expected on Feb 03, 2025.
Average growth rate+55.68%
Eisai Co Ltd reported annual 2024 earnings of 147.86 per share on May 14, 2024.
Average growth rate-14.89%
More ▼

Revenue history & estimates in JPY

Eisai Co., Ltd. had 2nd quarter 2025 revenues of 195.99m. This bettered the 180.79m consensus of the 5 analysts covering the company. This was 0.48% below the prior year's 2nd quarter results.
Average growth rate+2.68%
Eisai Co., Ltd. had revenues for the full year 2024 of 741.75m. This was 0.36% below the prior year's results.
Average growth rate+2.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.